Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanraplenib + Gilteritinib in FLT3-mutated R/R AML
NCT05028751Phase 2Terminated
- Sponsor
- Kronos Bio, Inc.
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lanraplenib in acute myeloid leukemia (AML), sponsored by Kronos Bio, Inc.. Started Aug 2022; status: terminated.
02
Drugs
lanraplenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05028751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028751.